Clinicoepidemiological Study of Locally Advanced Bladder Cancer: single institution experience. | ||||
| Egyptian Journal of Cancer and Biomedical Research | ||||
| Article 1, Volume 6, Issue 3, September 2022, Page 1-10 PDF (573.69 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jcbr.2022.134256.1258 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Shimaa Elmetwaly Attia  1; Soumaya Eteba2; Wafaa El-Beshbishi2; Mohammed Shabara2
| ||||
| 1Clinical oncology and nuclear medicine, faculty of medicine, mansoura university, mansoura , Egypt | ||||
| 2clinical oncology and nuclear medicine , faculty of medicine, mansoura university , mansoura, Egypt | ||||
| Abstract | ||||
| Background: Bladder cancer is the 9th most prevalent disease worldwide, ranking 13th in cancer mortality. Despite aggressive surgical treatments and systemic chemotherapy, patients with locally advanced bladder cancer (LABC) have a poor prognosis. In patients with muscle-invasive bladder cancer (MIBC), perioperative chemotherapy adds just a small but significant absolute survival benefit to surgery alone. Aim: This study aims to assess the clinical-epidemiological characteristics of LABC patients presented to the Clinical Oncology and Nuclear Medicine Department at Mansoura university hospitals from January 2010 to November 2016. Also, it assesses progression-free survival (PFS) and overall survival (OAS) of LABC patients with different treatment plans. Material and methods: This is a retrospective study that includes 135 patients presented with LABC. Data on demographics and clinical outcomes were collected from the patients' medical records for descriptive studies. Results: Our patient's ages ranged from 47 to 75 years old. The most common diagnoses stage in our patients were N0 (55.6%), followed by N2 (23.7%). As regards treatment modalities in our study, four main groups of treatment approaches were scheduled to include 124 patients either treated by radical surgery (9.6%), chemotherapy only (16.3%), radiotherapy (19.2%), or concomitant chemoradiotherapy (46.7%). Complete response (CR) was observed in 31.1% of studied patients and disease progression was documented in 11.1% Conclusion: MIBC accounts for about 75% of bladder malignancies. However, radical cystectomy is the gold standard for achieving high OAS rates. Another option is to adopt tri-modality therapy to preserve the native bladder and achieve satisfactory OAS and PFS data. | ||||
| Keywords | ||||
| bladder cancer; treatment; chemotherapy; radiotherapy; survival | ||||
|
Statistics Article View: 310 PDF Download: 258 |
||||
